Clearmind Medicine (NASDAQ: CMND) Shares Skyrocket Post Type A Meeting with FDA

Clearmind Medicine (NASDAQ: CMND) shares skyrocketed over 41% on Wednesday following the completion of a Type A meeting between the biotech company and the U.S. Food and Drug Administration (FDA). 

Clearmind Medicine (NASDAQ: CMND) has successfully concluded a Type A meeting with the U.S. Food and Drug Administration (FDA). The meeting focused on a clinical trial of the company involving its proprietary MEAI-based compound, CMND-100, designed for the treatment of Alcohol Use Disorder (AUD) utilizing a unique psychedelic-based therapy.

Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, expressed enthusiasm about the outcomes of the meeting, stating,

“We’re pleased to report we recently met with the FDA to align on the content of our IND resubmission for CMND-100. The meeting was informative and productive, and we’re eager to advance the U.S. regulatory process and potentially bring new hope for millions suffering from AUD by providing an innovative approach to overcome the challenges associated with the currently available treatments to date.”

CMND-100 contains MEAI (5-methoxy-2-aminoindane) as its active ingredient. MEAI, a novel psychoactive compound, has been shown to diminish the desire for alcohol consumption while inducing a euphoric alcohol-like experience. Its interaction with serotonergic receptors 5-HT1a, 5-HT2a, and 5-HT2b highlights its impact on the serotonergic system, a crucial player in regulating alcohol intake, reward, preference, and dependence.

In addition, MEAI interacts with alpha-2-adrenergic receptors α2A, α2B, and α2C, along with plasma membrane monoamine transporters for dopamine (DAT), norepinephrine (NET), and serotonin (SERT). These receptors and transporters are believed to influence alcohol-drinking behavior, making them potential molecular targets for interventions targeting alcohol and substance abuse.